TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8585698

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet (740 mg phytosterols/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet (29 mg phytosterols/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phytosterol-enriched diet
Number of subjects: 12
Study: 2705405

Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 67
Study: 411165

Group type: EXPERIMENTAL
Intervention: SCG 2% nasal solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31382717

Group type: EXPERIMENTAL
Intervention: C-arm digital metrology adjustment during percutaneous vertebroplasty
Number of subjects: 94

Group type: COMPARATOR
Intervention: C-arm adjustment based on experience (Control group)
Number of subjects: 94
Study: 28218554

Group type: EXPERIMENTAL
Intervention: New surgical techniques
Number of subjects: 0
Study: 26446505

Group type: COMPARATOR
Intervention: Chincup therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Facemask therapy (combined with rapid palatal expansion)
Number of subjects: 67
Study: 23650877

Group type: EXPERIMENTAL
Intervention: Perceptual training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conceptual training
Number of subjects: 0
Study: 21683039

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Life Skills Training (LST) program
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Combined LST + Strengthening Families Program: For Parents and Youth 10-14 (SFP10-14)
Number of subjects: 905
Study: 18079261

Group type: EXPERIMENTAL
Intervention: Weight loss program (non-macronutrient-specific energy restriction for 15 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 10
Study: 17043337

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg 3 times daily for 10 days (n = 43)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 87
Study: 12698083

Group type: EXPERIMENTAL
Intervention: Ursodiol, 800 mg per day for 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ursodiol and Placebo
Number of subjects: 30
Study: 10730733

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lumbar epidural analgesia
Number of subjects: 50
Study: 8959531

Group type: EXPERIMENTAL
Intervention: roxithromycin or minocycline (oral medication) and/or nadifloxacin cream or clindamycin hydrochloride lotion (topical medication) for 1‐8 weeks
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: nadifloxacin, ofloxacin, erythromycin, clindamycin hydrochloride, tetracycline hydrochloride, minocycline, doxycycline, ampicillin, cephalexin and gentamycin (susceptibility testing)
Number of subjects: 7
Study: 8195352

Group type: EXPERIMENTAL
Intervention: ZK 98,734 (12.5, 25, 50 or 100 mg twice daily for 4 days)
Number of subjects: 96
Study: 3308702

Group type: EXPERIMENTAL
Intervention: Safflower oil (linoleic acid)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbohydrate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cream (saturated fat)
Number of subjects: 21
Study: 29694685

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg monthly (QM)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Romosozumab followed by Denosumab 60 mg every 6 months (Q6M)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Romosozumab 210 mg QM
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Transition to Denosumab
Number of subjects: 364

Group type: COMPARATOR
Intervention: Transition to Placebo
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 364
Study: 24989147

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 118) - regularly exercising with a new sports companion for eight weeks
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (n = 102)
Number of subjects: 220
Study: 22922235

Group type: EXPERIMENTAL
Intervention: Trauma-focused day-treatment group program (2 days with three nonverbal and two group psychotherapy sessions per week)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trauma-focused day-treatment group program (same amount of sessions spread over 3 days per week)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 72
Study: 20473051

Group type: EXPERIMENTAL
Intervention: Active TCPRFT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham TCPRFT
Number of subjects: 50
Study: 18723251

Group type: EXPERIMENTAL
Intervention: SPC chart feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: SPC chart feedback in conjunction with structured diagnostic tools
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (no feedback)
Number of subjects: 75
Study: 15885789

Group type: COMPARATOR
Intervention: Focal laser photocoagulation (MP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Focal laser photocoagulation combined with posterior sub-Tenon's capsule triamcinolone injection (FL + PSTI)
Number of subjects: 60
Study: 12655794

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IL-2 plus GM-CSF
Number of subjects: 25
Study: 10553485

Group type: EXPERIMENTAL
Intervention: Biofeedback assisted relaxation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 18
Study: 7671437

Group type: EXPERIMENTAL
Intervention: L-arginine i.v. infusion (0.07 mmol/kg per min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 5
Study: 2151628

Group type: EXPERIMENTAL
Intervention: Heparan sulfate (200 mg, Hemovasal 100 b.i.d.)
Number of subjects: 40
Study: 6776858

Group type: EXPERIMENTAL
Intervention: Continuous oxygen (O2) therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Nocturnal O2 therapy
Number of subjects: 203
Study: 28810814

Group type: EXPERIMENTAL
Intervention: Vocational advice (VA) service
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Early vocational intervention
Number of subjects: 34
Study: 28510740

Group type: EXPERIMENTAL
Intervention: PROP (donor and recipient propofol)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: SEVO (donor and recipient sevoflurane)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PROSE (donor propofol and recipient sevoflurane)
Number of subjects: 57
Study: 25972158

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone 40 mg for days 1 to 4, oral cyclosporine 2.5 to 3 mg/kg daily for days 1 to 28, intravenous low-dose rituximab 100 mg for days 7, 14, 21, and 28.
Number of subjects: 20
Study: 23305576

Group type: EXPERIMENTAL
Intervention: HTK solution (16 patients)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional crystalloid cardioplegia (KK group, 16 patients)
Number of subjects: 32
Study: 20721895

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH) treatment
Number of subjects: 87
Study: 19950775

Group type: EXPERIMENTAL
Intervention: PPI with Ecabet Sodium (ES)
Number of subjects: 56

Group type: COMPARATOR
Intervention: PPI alone
Number of subjects: 56
Study: 17093107

Group type: EXPERIMENTAL
Intervention: Earnings supplement (qualifying by working full-time)
Number of subjects: 0
Study: 14986257

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 100

Group type: COMPARATOR
Intervention: No Vitamin A supplementation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multivitamins B-complex, C, and E
Number of subjects: 100
Study: 11717613

Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity >1.2 m/s suggesting severe MR in patients with normal EF
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity >1.2 m/s suggesting severe MR in patients with low EF
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Peak E‐wave velocity and E/A ratio
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Correlation of Peak E‐wave velocity with regurgitant fraction (RF)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Correlation of Peak E‐wave velocity with ejection fraction (EF)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: E‐wave deceleration, LV isovolumetric relaxation, and contraction time
Number of subjects: 135
Study: 9203756

Group type: EXPERIMENTAL
Intervention: Outpatient geriatric evaluation and management (GEM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual outpatient primary care (UPC)
Number of subjects: 0
Study: 8070258

Group type: EXPERIMENTAL
Intervention: Multiload 375
Number of subjects: 3655

Group type: COMPARATOR
Intervention: TCu380A
Number of subjects: 3655
Study: 3204249

Group type: EXPERIMENTAL
Intervention: Nalmefene, 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29091082

Group type: EXPERIMENTAL
Intervention: Linaclotide 72 μg
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Linaclotide 145 μg
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1223
Study: 28417527

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 26227018

Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 2 (group 1)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 4 (group 2)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 2 (group 1) with acute urinary retention (AUR)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 4 (group 2) with acute urinary retention (AUR)
Number of subjects: 113
Study: 23618489

Group type: COMPARATOR
Intervention: Daily Iron and Folic Acid Supplementation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Weekly Iron and Folic Acid Supplementation
Number of subjects: 120
Study: 21948069

Group type: EXPERIMENTAL
Intervention: Propofol (4 mg/kg loading dose administered intravenously)
Number of subjects: 52
Study: 18322858

Group type: EXPERIMENTAL
Intervention: modafinil 400 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: dextroamphetamine 20 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: caffeine 600 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 17159011

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 IU [alpha‐tocopherol acetate], on alternate days)
Number of subjects: 6377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6377
Study: 14616278

Group type: EXPERIMENTAL
Intervention: Bisection-morcellation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Myometrial coring
Number of subjects: 30
Study: 10795647

Group type: EXPERIMENTAL
Intervention: Budesonide aqueous nasal spray (256 microg daily)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray (200 microg daily)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study: 8650941

Group type: EXPERIMENTAL
Intervention: Wobenzym
Number of subjects: 55

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 55
Study: 1450046

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2a (3 MU/m2 s.c. three times weekly for 6 months)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: rIFN‐alpha 2a (3 MU/m2 five days/week for an additional 6 months after chemotherapy)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination of rIFN‐alpha 2a, streptozocin (2 g), and doxorubicin (40 mg/m2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination treatment
Number of subjects: 23
Study: 6483935

Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg (oral administration)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg (intravenous administration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (oral administration)
Number of subjects: 50
Study: 30772154

Group type: EXPERIMENTAL
Intervention: Di(2-propylheptyl) phthalate (DPHP) exposure measurement
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Urinary metabolite concentrations of DPHP
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Temporal trends of DPHP exposure
Number of subjects: 180
Study: 29557889

Group type: EXPERIMENTAL
Intervention: Manual resistance-based neck strengthening (n = 13)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control resistance exercise (n = 4)
Number of subjects: 17
Study: 26605836

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg, 0.05 mL intravitreous injections)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg, 0.05 mL intravitreous injections)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg, 0.05 mL intravitreous injections)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Aflibercept vs Bevacizumab
Number of subjects: 660

Group type: COMPARATOR
Intervention: Ranibizumab vs Bevacizumab
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Aflibercept vs Ranibizumab
Number of subjects: 660
Study: 24461903

Group type: EXPERIMENTAL
Intervention: Losmapimod 2.5 mg
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Losmapimod 15 mg
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 22538854

Group type: EXPERIMENTAL
Intervention: 1.1 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: 2.2 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: 4.4 × 10(11) platelets/m(2) per transfusion
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Control group (adults)
Number of subjects: 1242

Group type: EXPERIMENTAL
Intervention: All pediatric groups
Number of subjects: 1242
Study: 20585757

Group type: EXPERIMENTAL
Intervention: UretexTO
Number of subjects: 70

Group type: COMPARATOR
Intervention: PelviLaceTO
Number of subjects: 70
Study: 17580253

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 15642547

Group type: EXPERIMENTAL
Intervention: Distal balloon occlusion device
Number of subjects: 801

Group type: COMPARATOR
Intervention: No distal balloon occlusion device (control)
Number of subjects: 801
Study: 11972594

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9654837

Group type: EXPERIMENTAL
Intervention: 50 mg of proglumide with one-half analgesic dose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo with full analgesic dose
Number of subjects: 60
Study: 8605516

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CE) solution (6.9% providing 1.0 g CHO.kg body weight‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo solution (control group)
Number of subjects: 16
Study: 2668259

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 40
Study: 29240021

Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electroconvulsive shock (ECS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increasing electrical dosage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Increasing MST dosage
Number of subjects: 24
Study: 28676038

Group type: EXPERIMENTAL
Intervention: Oral sildenafil for 16 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral sildenafil
Number of subjects: 48
Study: 26260553

Group type: EXPERIMENTAL
Intervention: REM Desensitization
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 33
Study: 23307149

Group type: EXPERIMENTAL
Intervention: Endocytoscopy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 170
Study: 21586432

Group type: EXPERIMENTAL
Intervention: 0.3 M sucrose (intervention)
Number of subjects: 201

Group type: COMPARATOR
Intervention: 0.1 M sucrose (control)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Combined fresh and frozen cycles
Number of subjects: 201
Study: 19632969

Group type: EXPERIMENTAL
Intervention: 9 weeks of immediate-program-access as an add-on to treatment-as-usual (N = 320)
Number of subjects: 396

Group type: COMPARATOR
Intervention: 9-week delayed-access plus treatment-as-usual (N = 76)
Number of subjects: 396
Study: 16861168

Group type: EXPERIMENTAL
Intervention: Qi therapy without touching (QTN)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Qi therapy with touching (QTT)
Number of subjects: 24
Study: 12638397

Group type: EXPERIMENTAL
Intervention: Wood creosote 45 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wood creosote 90 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wood creosote 135 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wood creosote 180 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wood creosote 225 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10713659

Group type: EXPERIMENTAL
Intervention: CHOP plus high-dose tamoxifen (Group II)
Number of subjects: 98

Group type: COMPARATOR
Intervention: CHOP only (Group I)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 8874676

Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) applied to hand
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transcutaneous nerve stimulation (TNS) applied to foot (placebo)
Number of subjects: 10
Study: 1373949

Group type: EXPERIMENTAL
Intervention: Calcipotriol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Betamethasone valerate
Number of subjects: 20
Study: 3549879

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 19
Study: 29505379

Group type: EXPERIMENTAL
Intervention: Parent mentors
Number of subjects: 155
Study: 27138020

Group type: EXPERIMENTAL
Intervention: Subcutaneous suction drain (SD)
Number of subjects: 118

Group type: COMPARATOR
Intervention: No subcutaneous suction drain (no SD)
Number of subjects: 118
Study: 24863954

Group type: EXPERIMENTAL
Intervention: Patient-directed discharge letter (PADDLE)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 22659998

Group type: EXPERIMENTAL
Intervention: Malnutrition care plan (MCP) initiated immediately upon identification of malnutrition
Number of subjects: 143

Group type: COMPARATOR
Intervention: No immediate MCP; only commenced if referred by clinical staff
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Malnutrition screening using the Mini Nutritional Assessment (MNA) tool
Number of subjects: 143

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 143
Study: 20570824

Group type: EXPERIMENTAL
Intervention: Short Alcohol Withdrawal Scale (SAWS)
Number of subjects: 122
Study: 18634770

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 48
Study: 15714929

Group type: EXPERIMENTAL
Intervention: Involved field (IF) radiation
Number of subjects: 603

Group type: COMPARATOR
Intervention: Extended field (EF) radiation
Number of subjects: 603

Group type: COMPARATOR
Intervention: Total nodal irradiation (TNI)
Number of subjects: 603
Study: 12297203

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control diet without glutamine
Number of subjects: 84
Study: 10358788

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 2 mg kg‐1 hr‐1 and fentanyl 5 micrograms kg‐1 hr‐1 for the first 60 min and 3 micrograms kg‐1 hr‐1 for the next 90 min, and droperidol 0.1 mg kg‐1 (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous ketamine 2 mg kg‐1 hr‐1, droperidol 0.1 mg kg‐1 and fentanyl 50‐100 micrograms in a bolus intermittently as needed (Group B)
Number of subjects: 40
Study: 7579383

Group type: EXPERIMENTAL
Intervention: Sequential IL-3 and GM-CSF (schedule B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Concurrent IL-3 and GM-CSF
Number of subjects: 93

Group type: COMPARATOR
Intervention: IL-3 alone
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg IL-3
Number of subjects: 93
Study: 1979272

Group type: EXPERIMENTAL
Intervention: 4 mg dimetindene maleate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium chloride solution (placebo)
Number of subjects: 8
Study: 6767576

Group type: EXPERIMENTAL
Intervention: Brompheniramine maleate (antihistamine)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 31035472

Group type: COMPARATOR
Intervention: Whole Avocado (WA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Half Avocado (HA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-Fat Control Meal (CON)
Number of subjects: 31
Study: 28423931

Group type: EXPERIMENTAL
Intervention: Enhanced walking program (incentives, feedback, competitive challenges, monthly wellness workshops)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Standard walking program
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Increase in average daily steps
Number of subjects: 474
Study: 25470623

Group type: EXPERIMENTAL
Intervention: Dominant tinnitus pitch
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tinnitus pitch
Number of subjects: 129
Study: 22302614

Group type: EXPERIMENTAL
Intervention: GeniVida™ bone blend (GBB) - genistein (30 mg/day), vitamin D3 (800 IU/day), vitamin K1 (150 μg/day), polyunsaturated fatty acids (1 g/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Calcium only (placebo)
Number of subjects: 70
Study: 21462082

Group type: COMPARATOR
Intervention: Selenium-enriched yeast (247 μg/day for 9 months)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Free-living adults
Number of subjects: 336
Study: 18282776

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy, starting dose 0.003 mg/kg/day for 8 weeks, then adjusted based on serum IGF-I levels
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 71